30.17
Lenz Therapeutics Inc stock is traded at $30.17, with a volume of 273.09K.
It is down -1.02% in the last 24 hours and down -7.25% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$30.48
Open:
$30.24
24h Volume:
273.09K
Relative Volume:
0.91
Market Cap:
$860.51M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-5.3901
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-1.92%
1M Performance:
-7.25%
6M Performance:
+13.04%
1Y Performance:
+28.11%
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LENZ
Lenz Therapeutics Inc
|
30.17 | 869.35M | 0 | -69.47M | -73.92M | -5.5973 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-14-25 | Resumed | Piper Sandler | Overweight |
Mar-18-25 | Initiated | TD Cowen | Buy |
Sep-27-24 | Initiated | Raymond James | Outperform |
Aug-12-24 | Initiated | H.C. Wainwright | Buy |
Apr-15-24 | Initiated | Leerink Partners | Outperform |
Apr-15-24 | Initiated | William Blair | Outperform |
Apr-10-24 | Initiated | Citigroup | Buy |
Mar-27-24 | Initiated | Piper Sandler | Overweight |
Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-14-22 | Initiated | BTIG Research | Buy |
Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-20-21 | Initiated | Morgan Stanley | Overweight |
Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
A Quick Look at Today's Ratings for LENZ Therapeutics(LENZ.US), With a Forecast Between $40 to $60 - 富途牛牛
Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops - TipRanks
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target raised to $56 from $48 at H.C. Wainwright - Investing.com Australia
What are LENZ Therapeutics Inc. company’s key revenue driversMaximize gains with timely market signals - Jammu Links News
How many analysts rate LENZ Therapeutics Inc. as a “Buy”Phenomenal wealth increase - Jammu Links News
What analysts say about LENZ Therapeutics Inc. stockRecord-setting profit potential - Jammu Links News
When is LENZ Therapeutics Inc. stock expected to show significant growthGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for LENZ Therapeutics Inc.Free Expert Stock Watchlist - Jammu Links News
Is LENZ Therapeutics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
LENZ Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of LENZ Therapeutics Inc. stockHigh-octane investment gains - Jammu Links News
What catalysts could drive LENZ Therapeutics Inc. stock higher in 2025Achieve superior returns with professional insights - Jammu Links News
What is the risk reward ratio of investing in LENZ Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
How volatile is LENZ Therapeutics Inc. stock compared to the marketLightning-fast growth - Jammu Links News
Why is LENZ Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent returns with proven methods - Jammu Links News
Volume spikes in LENZ Therapeutics Inc. stock – what they meanFree Real Time Alerts Based on AI Prediction - Newser
LENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume After Analyst Upgrade - Defense World
Is it time to cut losses on LENZ Therapeutics Inc.Free Step-by-Step Stock Investment Guide - Newser
Using data models to predict LENZ Therapeutics Inc. stock movementTen-Year Sector Performance and Summary Analysis - Newser
William Blair Expects Weaker Earnings for LENZ Therapeutics - Defense World
Published on: 2025-08-01 19:39:34 - Newser
Citi maintains Buy rating on LENZ Therapeutics, raises PT to $52 from $49. - AInvest
LENZ Therapeutics announces FDA Approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia - Eyes On Eyecare
FDA approves LENZ Therapeutics' VIZZ for presbyopia - Eyes On Eyecare
Eyes on the prize: FDA approves Lenz’s drops for presbyopia - BioWorld MedTech
LENZ Therapeutics' Eye Drop Scores First FDA Approval… - inkl
LENZ Therapeutics gets FDA nod for presbyopia eye drop (LENZ) - Seeking Alpha
LENZ Therapeutics Stock Soars 12.5% on FDA Approval of VIZZ - AInvest
Analysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Applying big data sentiment scoring on LENZ Therapeutics Inc.Free Risk-Adjusted Picks With Exit Strategy - Newser
LENZ Therapeutics Announces FDA Approval of VIZZ for Treatment of Presbyopia - VisionMonday.com
Has LENZ Therapeutics Inc. found a price floorFree Triple Digit Return Stock Predictions - Newser
Citigroup maintains Buy rating on LENZ Therapeutics, raises PT to $49. - AInvest
Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Conexiant
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops - Investing.com Australia
Lenz Therapeutics stock rises after FDA approves presbyopia eye drops By Investing.com - Investing.com Canada
LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop - MSN
FDA Approval: Revolutionary 10-Hour Eye Drops Promise Freedom from Reading Glasses - Stock Titan
Lenz (LENZ) Q2 Revenue Jumps 604% - The Motley Fool
Lenz Therapeutics Prepares for LNZ100 Launch - TipRanks
Is a relief rally coming for LENZ Therapeutics Inc. holdersFree AI Powered High Return Stock Calls - Newser
FY2025 EPS Estimate for LENZ Therapeutics Lifted by Analyst - Defense World
LENZ Therapeutics gains on NDA submission in China for presbyopia drug LNZ100 - MSN
LENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on schedule - MSN
Biotech Stocks Under FDA Review in August 2025: LENZ Therapeutics and PharmaTher Holdings - AInvest
LENZ Therapeutics shares surge as FDA review of presbyopia drug on track - Investing.com Australia
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss - Yahoo Finance
How Efficient Is LENZ Therapeutics Inc. at Controlling Operating CostsStrong Buy With Technical Confidence Supported - metal.it
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics and the Imminent FDA Decision for LNZ100: A High-Conviction Biotech Play Ahead of PDUFA - AInvest
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Versant Venture Capital VI, L. | 10% Owner |
Jun 27 '25 |
Sale |
30.46 |
200,000 |
6,093,000 |
1,767,275 |
Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.25 |
133,924 |
4,051,201 |
1,967,275 |
Versant Venture Capital VI, L. | 10% Owner |
Jun 20 '25 |
Sale |
30.35 |
100,877 |
3,061,617 |
1,047,912 |
Versant Venture Capital VI, L. | 10% Owner |
Jun 18 '25 |
Sale |
29.95 |
100,000 |
2,995,000 |
1,148,789 |
Versant Venture Capital VI, L. | 10% Owner |
Jun 10 '25 |
Sale |
29.00 |
350,000 |
10,150,000 |
1,248,789 |
Olsson Shawn | Chief Commercial Officer |
Apr 09 '25 |
Option Exercise |
2.08 |
1,400 |
2,912 |
4,733 |
Schimmelpennink Evert B. | President, CEO and Secretary |
Mar 07 '25 |
Option Exercise |
1.04 |
4,200 |
4,368 |
49,200 |
Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):